List of Zembrace Symtouch drug patents

Zembrace Symtouch is owned by Upsher Smith Labs.

Zembrace Symtouch contains Sumatriptan Succinate.

Zembrace Symtouch has a total of 2 drug patents out of which 0 drug patents have expired.

Zembrace Symtouch was authorised for market use on 28 January, 2016.

Zembrace Symtouch is available in solution;subcutaneous dosage forms.

Zembrace Symtouch can be used as treatment of migraine.

The generics of Zembrace Symtouch are possible to be released after 29 January, 2036.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10537554 UPSHER SMITH LABS Pharmaceutical composition for treating migraine
Jan, 2036

(13 years from now)

US11364224 UPSHER SMITH LABS Pharmaceutical composition for treating migraine
Jan, 2036

(13 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 28 January, 2016

Treatment: Treatment of migraine

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in